Cover [Abstract] Document Information [Table] Document Information [Line Items] Document Type Document Annual Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Auditor Firm ID Auditor Name Auditor Location Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Consolidated Balance Sheets Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash Cash Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Right-of-use asset Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Current liabilities Current liabilities: Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical costs. Accrued Liabilities, Clinical Trial, Current Clinical trial accrued liabilities Amount of accrued expenses and liabilities classified as other, due within one year or the normal operating cycle, if longer. Accrued Expenses And Other Liabilities, Current Accrued expenses and other current liabilities Total Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current As of ending balance As of beginning balance Warrant liabilities Other Liabilities, Current Related party payable Other Liability, Current, Related Party [Extensible Enumeration] Operating Lease, Liability, Current Short-term portion Lease liability, short-term Liabilities, Current Total current liabilities Operating Lease Liability, Noncurrent Long-term portion Lease liability, long-term Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Preferred Stock, Value, Issued Preferred stock, $0.001 par value per share; 10,000 shares authorized and no shares issued or outstanding as of December 31, 2024 and 2023 Common Stock, Value, Issued Common stock, $0.001 par value per share, 100,000 shares authorized as of December 31, 2024 and 2023; 8,637 and 4,906 shares issued and outstanding as of December 31, 2024 and 2023, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance at end of period Balance at beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollar per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value (in dollar per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Operations Operating Expenses [Abstract] Operating expenses Research and Development Expense (Excluding Acquired in Process Cost) Research and development General and Administrative Expense General and administrative Total general and administrative Costs and Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other income Fair Value Adjustment of Warrants Change in fair value of warrant liabilities Change in fair value of warrant liabilities Interest Income (Expense), Net Interest income Other Expenses Total other income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Provision for income taxes Provision for income taxes Net loss and comprehensive net loss Net loss Earnings Per Share, Basic and Diluted [Abstract] Loss per share: Earnings Per Share, Basic Loss per share of common stock, basic (in dollars per share) Loss per share of common stock, basic (in dollars per share) Earnings Per Share, Diluted Loss per share of common stock, diluted (in dollars per share) Loss per share of common stock, diluted (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average shares of common stock outstanding: Weighted Average Number of Shares Outstanding, Basic Weighted average shares of common stock outstanding, basic (in shares) Weighted average shares of common stock, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average shares of common stock outstanding, diluted (in shares) Weighted average shares of common stock, diluted (in shares) Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-in Capital Accumulated Deficit Shares, Issued Balance at end of period (shares) Balance at beginning of period (shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Stock Issued During Period, Value, Stock Options Exercised Issuance of stock from exercise of warrants Reclassification of warrant liabilities upon exercise of warrants Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of stock from exercise of warrants (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Amount of common stock and warrants issued during the period. Stock Issued During Period, Value, Common Stock and warrants Issuance of common stock and warrants under the securities purchase agreements, net of issuance costs Number of common stock and warrants issued during the period. Stock Issued During Period, Shares, Common Stock and warrants Issuance of common stock and warrants under the securities purchase agreements, net of issuance costs (in shares) Adjustments to Additional Paid in Capital, Warrant Issued Issuance of placement agent warrants Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of stock for vested restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of stock for vested restricted stock units (in shares) Restricted Stock, Value, Shares Issued Net of Tax Withholdings Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes (in shares) The amount of issuance costs related to stock and warrants. Stock And Warrants Issuance Costs Stock and warrants issuance costs Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation. Stock-based compensation Operating Lease Right Of Use Asset Amortization Expense Non-cash lease expense Depreciation Depreciation Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued and other liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net cash provided by (used in) investing activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price. Proceeds From Issuance Of Common Stock And Warrants Proceeds from the issuance of common stock and warrants under the securities purchase agreements Proceeds from Warrant Exercises Common stock for no additional consideration Proceeds from exercise of warrants Payments of Financing Costs Payments of issuance costs in connection with the securities purchase agreements Payment, Tax Withholding, Share-Based Payment Arrangement Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by (used in) financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash at end of period Cash at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental non-cash investing and financing transactions: Amount of fair value of warrants issued to placement agent Fair value of warrants issued to placement agent Fair value of warrants issued to placement agent Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease liabilities Business, basis of presentation, new accounting standards and summary of significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Business, basis of presentation, new accounting standards and summary of significant accounting policies Prepaid expenses and other current assets The entire disclosure for prepaid expense and other current assets at the end of the reporting period. Prepaid Expense And Other Current Assets [Text Block] Prepaid expenses and other current assets Property and equipment, net Property, Plant and Equipment Disclosure [Text Block] Property and equipment, net The entire disclosure for current liabilities at the end of the reporting period. Current liabilities [Text Block] Current liabilities Related party Related Party Transactions Disclosure [Text Block] Related party Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Stockholders' equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' equity Significant segment expenses Segment Reporting Disclosure [Text Block] Significant segment expenses Income taxes Income Tax Disclosure [Text Block] Income taxes Loss per share of common stock Earnings Per Share [Text Block] Loss per share of common stock Fair value measurements Fair Value Disclosures [Text Block] Fair value measurements Basis of Presentation and Significant Accounting Policies [Text Block] Basis of presentation New Accounting Pronouncements, Policy [Policy Text Block] New accounting standards Use of Estimates, Policy [Policy Text Block] Estimates and assumptions Cash and Cash Equivalents, Policy [Policy Text Block] Cash Property, Plant and Equipment, Policy [Policy Text Block] Property and equipment Lessee, Leases [Policy Text Block] Leases Disclosure of accounting policy for determining the warrant liabilities. Warrant Liabilities, Policy [Policy Text Block] Warrant liabilities Fair Value of Financial Instruments, Policy [Policy Text Block] Fair value of financial instruments Segment Reporting, Policy [Policy Text Block] Segment reporting Research and Development Expense, Policy [Policy Text Block] Research and development costs In Process Research and Development, Policy [Policy Text Block] Acquired in-process research and development Selling, General and Administrative Expenses, Policy [Policy Text Block] General and administrative expenses Disclosure of accounting policy for patent costs. Patent Cost Policy [Policy Text Block] Patent costs Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based compensation Income Tax, Policy [Policy Text Block] Income taxes Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign currency translation Stockholders' Equity, Policy [Policy Text Block] Comprehensive loss Earnings Per Share, Policy [Policy Text Block] Loss per share of common stock Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations Commitments and Contingencies, Policy [Policy Text Block] Loss contingencies Reclassification, Comparability Adjustment [Policy Text Block] Reclassification of prior year presentation Deferred Costs Capitalized Prepaid And Other Assets [Table Text Block] Schedule of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block] Schedule of warrant liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of outstanding warrants Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense Share-Based Payment Arrangement, Activity [Table Text Block] Schedule of outstanding awards issued pursuant to our stock-based award plans and inducement grants Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of RSUs and related transactions Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of the status of outstanding and exercisable options and related transactions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used in the Black Scholes option-pricing model Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of significant segment expenses Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of loss before income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of components of income tax provision Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax assets and liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted loss per share of common stock Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding securities which were not included in the calculation of diluted earnings per share of common stock Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value measurements on a recurring basis Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Revision of Prior Period [Axis] Revision of Prior Period [Domain] Revision of Prior Period, Reclassification, Adjustment [Member] Range [Axis] Range [Domain] Minimum Maximum Subsidiary, Sale of Stock [Line Items] Business, basis of presentation, new accounting standards and summary of significant accounting policies Property, Plant and Equipment, Useful Life Estimated useful life Prepaid Insurance Insurance Deposits Assets, Current Deposits Other Prepaid Expense, Current Other prepaid expenses Property, Plant and Equipment, Gross Office equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Employee-related Liabilities, Current Employee related costs Accrued Professional Fees, Current Professional service fees Other Accrued Liabilities, Current Other Amount of extinguishment of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Extinguishment Reclassification of warrant liabilities upon exercise of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value of warrant liabilities Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to series A and series B warrants issued in November 2022. November 2022 Series A and B Class of Warrant or Right [Line Items] Warrant liabilities Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of warrants per unit Exercise Price of Warrants or Rights Exercise Price Warrants exercise price Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Related Party [Member] Related party Related Party Transaction [Axis] Related Party Transaction [Domain] Exclusive worldwide license to certain patent rights to make, use, sell, offer for sale and import product. 2022 License Agreements The License Agreement covers the rights to DA-1726 for treatment of obesity and NASH. DA-1726 [Member] DA-1726 The License Agreement covers the rights to DA-1241 for treatment of NASH . DA-1241 [Member] DA-1241 Represents the information pertaining to Shared Services Agreement. Shared Services Agreement Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Dong-A. Dong-A [Member] Dong-A Related Party Transaction [Line Items] Related party Research and Development Expense R&D expenses Total research and development Amount of developmental and regulatory milestone payments eligible to be received under the license agreement. License Agreement, Developmental And Regulatory Milestone To Be Received Developmental and regulatory milestone payment eligible to be received The period for failing to cure the beach, the agreement may get terminated. Period for Fail to Cure the Breach, May Terminate Agreement Period for failing to cure the beach, the agreement may get terminated The cure period for beaching party if cannot be cured within the 60-day period. Cure Period for Breaching Party Cure period for beaching party if cannot be cured within the 60-day period The period for petition for termination notice for the other party's material breach that is not cured. Period for Termination Notice Period for termination notice when material breach not cured The cure period for petition for bankruptcy. Cure Period for Petition for Bankruptcy Cure period for petition for bankruptcy Refers to milestones accrued. Milestones Accrued Amount of milestones accrued The Percentage of common stock outstanding. Percentage of common stock outstanding Percentage of common stock outstanding Other Liability, Current, Related Party, Name [Extensible Enumeration] Lessee, Lease, Description [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Represents the information pertaining to New Corporate Headquarters Lease. New Corporate Headquarters Lease Represents the information pertaining to Old Bolton Lease. Old Boston Lease Former Corporate Headquarters Lease Lessee, Lease, Description [Line Items] Commitments and Contingencies Lessee, Operating Lease, Term of Contract Term of contract Lessee, Operating Lease, Renewal Term Renewal term Operating Lease, Expense Rental expense Operating Lease, Payments Operating lease cash payments Lessee, Operating Lease, Discount Rate Operating lease discount rate Operating Lease, Liability Lease asset liability Total Operating Lease Liabilities, Payments Due [Abstract] Maturity of the lease liability was as follows (in thousands): Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2025 2021 2026 Lessee, Operating Lease, Liability, Payments, Due Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less effect of discounting Asset Acquisition [Table] Asset Acquisition [Line Items] Contractual Obligation Contingent liabilities recorded Gain Contingency, Unrecorded Amount Contingent assets recorded No definition available. License and Collaboration Agreement Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] License Agreements Employee eligibility age criteria under defined contribution plan. Defined Contribution Plan, Employee Eligibility Age Minimum age of employee to cover under the plan Percentage of employee contributions may be deferred to a defined contribution plan. Defined Contribution Plan, Employee Contribution Deferred, Percentage Employee compensation deferred percentage Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Defined Contribution Plan, Employer Matching Contribution, Vesting Percentage Employer matches vesting period Percentage of employee contribution vested on contribution made by employee. Employee Compensation Vesting Percentage on Contribution Percentage of employee contribution vested on their contribution Defined Contribution Plan, Employer Discretionary Contribution Amount Amount of discretionary matching contributions on employee deferrals Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Common Stock Represents the voting rights per share for common stock of the entity. Common Stock Voting Rights Per Share Common stock, vote per share Dividends, Common Stock [Abstract] Dividends Rights Dividends, Common Stock, Cash Dividends declared Sale of Stock [Axis] Sale of Stock [Domain] Represents the information pertaining to June 2024 offering. June 2024 Offering [Member] June 2024 Offering Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Represents the information pertaining to Securities Purchase agreement. Securities Purchase Agreement [Member] Securities purchase agreement Dong-A Represents the information pertaining to pre-funded warrants. Pre-Funded Warrants [Member] Pre-Funded Warrants Represents information pertaining to Series A Warrant. Series A warrant Represents information pertaining to Series B Warrant. Series B Warrant Series B warrants Represents information pertaining to PIPE common warrants. PIPE Common Warrants [Member] PIPE common warrants Represents the information pertaining to Placement Agent Warrants. Placement Agent Warrants [Member] Placement agent warrants Represents the information pertaining to Placement Agent Contingent Warrants. Placement Agent Contingent Warrants [Member] Placement Agent Contingent Warrants Placement agent contingent warrants The number of securities purchase agreements entered during the period. Number of Securities Purchase Agreements Entered Number of Securities Proceeds from Issuance or Sale of Equity Consideration received Common Stock Issued Shares issued (in shares) Shares Issued, Price Per Share Offering shares (Per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Shares of common stock issuable for Issued and outstanding warrants Warrants to purchase shares of common stock The period from date of stockholders approval considered for warrants expiry term. Period From Date of Stockholders Approval Considered for Warrants Expiry Term Expired terms The threshold period following the public announcement of the Company receiving positive Phase 1 multiple ascending dose ("MAD") data for expiry of warrants. Threshold Period Following the Public Announcement of Receiving Positive Phase 1 Multiple Ascending Dose Data For Expiry of Warrants Threshold period following the public announcement of receiving positive phase 1 multiple ascending dose data for expiry of warrants The threshold percentage for beneficial ownership. Threshold Percentage For Beneficial Ownership Maximum percentage of outstanding common stock The effective period for changing beneficial ownership limitation from receipt of written notice from holder. Effective Period For Changing Beneficial Ownership Limitation From Receipt of Written Notice From Holder Number of days written notice The percentage of placement agent gee on gross proceeds of offering. Percentage of Placement Agent Fee Percentage of placement agent fee The amount of non-accountable expenses and clearing costs as placement agent fees. Placement Agent Fees, Non-accountable Expenses And Clearing Costs Non-accountable expenses and clearing costs The maximum number of shares exercisable through warrants as a percent on total shares and warrants sold in the offering. Percentage of Shares and Warrants Sold in Offering, Maximum Shares exercisable Through Warrants Percentage of common stock sold The premium of offering price for warrants exercise price in percentage. Premium of Offering Price For Exercise Price, Percentage Premium of offering price per share (as a percent) The weighted average fair value per share of warrants. Weighted Average Fair Value Per Share of Warrants Weighted average fair value of warrants The period after the date that the shares of common stock underlying the Placement Agent Warrants are registered for warrants termination. Period After the Date The Shares of Common Stock Underlying the Placement Agent Warrants Registered For Warrants Termination Terminate of common stock Warrants Not Settleable in Cash, Fair Value Disclosure Non-cash issuance cost Represents the warrants with exercise price $44,820.00. Warrants Exercise Price 44,820.00 [Member] Warrants Exercise Price 44,820.00 Represents the warrants with exercise price $3,000.00. Warrants Exercise Price 3,000.00 [Member] Warrants Exercise Price 3,000.00 Represents the warrants with exercise price of $1,447.20 Warrants Exercise Price 1,447.20 [Member] Warrants Exercise Price 1,447.20 Represents the warrants with exercise price of $900.00 Warrants Exercise Price 900.00 [Member] Warrants Exercise Price 900.00 Represents information pertaining to November 2022 Series B warrants with exercise price of $ 0.00. November 2022 Series B Warrant Exercise Price 0.00 [Member] November 2022 Series B Represents the warrants issued through placement agents in June 2024 with exercise price 4.9125. June 2024 Placement Agent, Warrant Exercise Price 4.9125 [Member] June 2024 Placement Agent Represents the warrants issued through pre-funded warrants scheme in June 2024 with exercise price 0.0010. June 2024 Pre-Funded, Warrant Exercise Price 0.0010 [Member] June 2024 Pre-funded Represents the warrants issued as series A in June 2024 with exercise price 3.9300. June 2024 SeriesA, Warrant Exercise Price 3.9300 [Member] June 2024 Series A Represents the warrants issued as series B in June 2024 with exercise price 3.9300. June 2024 Series B, Warrant Exercise Price 3.9300 [Member] June 2024 Series B Warrant liabilities Warrants Class of Warrant or Right, Outstanding Number of Warrants Number of warrants or rights outstanding and exercisable. Class of Warrant or Right, Outstanding and Exercisable Outstanding and exercisable warrants Number of warrants exchanged for the securities called by warrants. Class of Warrant or Right, Securities Called by Each Warrant or Right, Number of Warrants Exchanged Number of warrants exchanged Number of warrants into which each share may be converted. Class of Warrant or Right, Number of Warrants Called by Each Share of Stock Exercised warrants Class of Warrant or Right, Number of Warrants Issued Number of Warrants Issued Number of warrants Class of Warrant or Right, Warrant Term Warrants term Number of warrants exercised for the securities. Class Of Warrant Or Right Securities Called By Each Warrant Or Right, Number Of Warrants Exercised Pre-Funded warrants issued Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Domain] General and administrative General and administrative Research and Development Expense [Member] Research and development Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Payment Arrangement, Expense Stock-based compensation Plan Name [Axis] Plan Name [Domain] Represents the information pertaining to 2022 plan. Stock Plan 2022 [Member] 2022 Plan Represents the information pertaining to 2019 stock plan. 2019 Plan 2019 Plan Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Number of shares added (In shares) The period over which the shares reserved for further issuance under share based compensation will increase annually. Share-based Compensation Arrangement by Share-based Payment Award, Period Number of shares reserved for further issuance Increase Annually Period of automatic increase in shares reserved Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Percentage of the common shares outstanding (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Restricted Stock Units (RSUs) [Member] Restricted stock units RSUs Represents the information pertaining to 2021 stock plan. 2021 Inducement Plan 2021 Inducement Plan Represents the information pertaining to Stock Plans 2019, 2022 And Inducement Plan. Stock Plan 2019, 2022 And Inducement Plan [Member] Stock Plan 2019, 2022 And Inducement Plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, Number, Ending Balance (in shares) Outstanding, Number, Beginning Balance (in shares) Stock options Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number RSU's Fair value, Ending balance (in shares) RSU's Fair value, Beginning balance (in shares) RSUs Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Remaining shares of common stock available for future issuance Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized share-based compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized share-based compensation - Weighted average period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period RSU's, Number grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSU's, Number Forfeited/Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period RSU's, Number Vested and Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value RSU's Fair value, Ending balance (per share) RSU's Fair value, Opening balance (per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value RSU's Fair value, grants in period (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value RSU's Fair value, Forfeited/Cancelled in period (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value RSU's Fair value, vested in period (per share) Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding Balance Outstanding, Aggregate Fair Value, ending balance Outstanding, Aggregate Fair Value, beginning balance Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding Outstanding, Aggregate Fair Value, Vested and released The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number RSU's Vested and Deferred Release, Ending balance (in shares) RSU's Vested and Deferred Release, Beginning balance (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that are exercisable during the reporting period. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercisable in Period RSUs, Vested and Deferred Release (in shares) Per share or unit weighted-average fair value of vested award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value RSU's Vested Fair value, Ending balance (per share) RSU's Vested Fair value, Opening balance (per share) The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan exercisable. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Grant Date Fair Value RSUs, Vested and Deferred Release (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Intrinsic value, ending balance Intrinsic value, opening balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Stock Options, Additional Disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Forfeited and cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options Exercisable, Number, Ending Options Exercisable, Number, Beginning Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Forfeited and cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options Exercisable, Exercise price, ending (in dollars per share) Options Exercisable, Exercise price, beginning (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options, Outstanding, Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and exercisable (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options Exercisable, Intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Represents the information pertaining to a single reportable segment. Single Reportable Segment [Member] Single reportable segment Segment Reporting Information [Line Items] Significant segment expenses Research and Development Expense [Abstract] Research and development The amount of expense provided in the period for Clinical trials. Clinical Trials Expense Clinical trials The amount of costs under the shared services agreement. Costs under Shared Services Agreement Costs under the Shared Services Agreement with Dong-A (related party) The amount of expense provided in the period for labor and related services incurred in Research and development. Labor And Related Expense, Research And Development Employee compensation and benefits The amount of expense provided in the period for consultancy services incurred in Research and development. Consulting Fee, Research And Development Consulting Other Research and Development Expense Other General and Administrative Expense [Abstract] General and administrative The amount of expense provided in the period for legal costs and professional costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Legal And Professional Fees Legal and professional fees The amount of expense provided in the period for consultancy services incurred in General and administrative. Consulting Fee, General And Administrative Consulting The amount of expense provided in the period for labor and related services incurred in General and administrative. Labor And Related Expense, General And Administrative Employee compensation and benefits Other General and Administrative Expense Other Operating Expenses Total operating expenses Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Loss before Income taxes: Income (Loss) from Continuing Operations before Income Taxes, Domestic United States Income (Loss) from Continuing Operations before Income Taxes, Foreign Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract] Income tax (benefit) expense: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred Deferred Federal, State and Local, Tax Expense (Benefit) United States Deferred Foreign Income Tax Expense (Benefit) Foreign Deferred Income Tax Expense (Benefit) Total deferred income tax (benefit) expense The amount of valuation allowance of domestic income tax expense (benefit). Valuation Allowance of Domestic Income Tax Expense Benefit Change in valuation allowance - United States The amount of valuation allowance of foreign income tax expense (benefit). Valuation Allowance of Foreign Income Tax Expense Benefit Change in valuation allowance - Foreign Effective Income Tax Rate Reconciliation, Percent [Abstract] Reconciliation of income tax: Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Income taxes at federal statutory rate (as a percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State income tax, net of federal benefit (as a percent) Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate Change in state tax rate (as a percent) Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to change in fair value of warrants. Effective Income Tax Rate Reconciliation, Change in Fair Value of Warrants Change in fair value of warrant liabilities (as percent) Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other (as a percent) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Valuation allowance (as a percent) Effective Income Tax Rate Reconciliation, Percent Effective tax rate (as a percent) Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Federal Components of Deferred Tax Assets and Liabilities [Abstract] Significant components of deferred tax assets and liabilities: Components of Deferred Tax Assets [Abstract] Gross deferred income tax assets: Deferred Tax Assets, Operating Loss Carryforwards Federal and state operating loss carryforwards Deferred Tax Assets Acquired Intangibles Acquired intangibles Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Stock-based compensation Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability. Deferred Tax Assets, Lease Liability Lease liability Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs. Deferred Tax Assets, Capitalized Research and Development Costs Capitalized R&D expenses Deferred Tax Assets, Other Other Deferred Tax Assets, Tax Credit Carryforwards, Research R&D credit carryforwards Deferred Tax Assets, Gross Total gross deferred income tax assets Deferred Tax Assets, Valuation Allowance Valuation allowance Valuation allowance Deferred Tax Assets, Net of Valuation Allowance Gross deferred tax assets, net of valuation allowance Components of Deferred Tax Liabilities [Abstract] Gross deferred tax liabilities: Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets Deferred Tax Liabilities, ROU Asset ROU asset Deferred Tax Liabilities, Other Other Deferred Tax Liabilities, Gross Gross deferred income tax liabilities Deferred Tax Assets, Net Deferred income tax assets, net State and Local Jurisdiction [Member] State Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract] Operating loss carryforwards: Operating Loss Carry Forward Research Credit Research credit carry forward Operating Loss Carryforwards Operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Foreign Foreign operating loss carryforwards Income Tax Uncertainties [Abstract] Income tax: Unrecognized Tax Benefits Uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Interest or penalties Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrants Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Loss per share of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares) Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Recurring Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 2 Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of financial instruments Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount Warrant liabilities Financial Liabilities Fair Value Disclosure Total